New Virtual Histology Sub-Study Evaluates Impact Of Repatha ® (Evolocumab) On Coronary Artery Plaque Composition

Late-Breaking Clinical Trial Presented at ESC 2017 THOUSAND OAKS, Calif., Aug. 29, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from an exploratory virtual histology sub-study of the Repatha® (evolocumab) GLAGOV Phase 3 coronary intravascular ultrasound imaging trial that looked at coronary artery plaque composition. While virtual histology demonstrated an increase in dense calcium in coronary artery plaques in both the statin and Repatha arms, it did not detect a statistically significant difference between the two treatment groups. However, the observed directional trend in increased dense calcium with corresponding reduction in low-density lipoprotein cholesterol ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news